培美曲赛对比多西他赛联合顺铂一线治疗ECOG 0～2分的老年晚期非小细胞肺癌的临床观察

目的：观察培美曲赛对比多西他赛联合顺铂一线治疗老年晚期非小细胞肺癌（ NSCLC ）且ECOG＝0～2分患者的疗效及毒性反应。方法分析45例晚期非小细胞肺癌患者，应用培美曲塞联合顺铂（ PC组）治疗24例，多西他赛联合顺铂（ DC组）治疗21例，2～6周期后评价疗效及不良反应。结果培美曲塞组CR 0例， PR 4例，SD 11例，PD 9例，中位生存期为8．7个月，多西他赛组CR 0例，PR 3例，SD 8例，PD 10例，中位生存期为8．5个月。两组比较，DCR和中位生存期差异均无统计学意义（ P＞0．05）。培美曲塞组中性粒细胞减少的发生率低于多西他赛（P＜0．05）组。结论培美曲塞或多西他赛联合顺铂治疗晚期非小细胞肺癌疗效相当，但培美曲塞不良反应的发生率较低。

The Comparison of Pemetrexed Combined with Cisplatin and Docetaxel Combined with Cisplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer,ECOG 0~2

Objective To observe the efficacy and toxicity of pemetrexed combined with cisplatin and do-cetaxel combined with cisplatin in elderly patients with advanced non-small cell lung cancer,ECOG 0~2.Methods Forty-five patiets of ECOG 0~2 were randomly assigned to two groups .The study group （ n=24 ） accepted pemetrexed 500mg/m2 and cisplatin 25mg/m2 d1~3 every 3weeks as a cycle.and the control group（n=21） docetaxel 75mg/m2 d1 and cisplatin 25mg/m2 d1~3 every 3 weeks as a cycle;Evaluation of efficacy and adverse was performed at end of 2~6 cycles.Results There were no CR patients in two groups ,and in the study group there were 4 patients of PR ,11 pa-tients of SD and 9 patients of PD,DCR（ PR＋CR＋SD） was 62.5%;but in the contral group,3 patients of PR,8 pa-tients of SD and 10 patients of PD,DCR（PR＋CR＋SD） was 52.4%.Conclusion The study group has the same treat-ment effect and less adverse reaction in patients of ECOG 0~2 in advanced non-small-cell lung cancer .